AstraZeneca Promotes Depression Education & Awareness

Nearly 10 percent of the total adult population in the U.S. has symptoms of depression, according to DepressionStatistics.org. The chronic illness can disrupt everyday life for an individual suffering from the condition. Depression may also result in anxiety, suicidal thoughts and substance abuse if not treated. Rehabilitation facilities offer treatment options for individuals suffering from drug abuse and addiction as a result of depression.

This week, AstraZeneca, a pharmaceutical company, announced that it will be launching a “Take on Depression” campaign to support individuals, and their loved ones, who struggle with this health problem. The initiative will be promoted in the form of a Facebook fan page and a Twitter account through which users can access information on bipolar and major depressive disorder (MDD).

“[We believe that] the best way to help those who are still struggling with bipolar depression and major depressive disorder is to provide them with resources and tools to help understand their illness and manage their symptoms,” said Sandy Sommer, executive director at AstraZeneca.

Bipolar disorder affects 5.7 million Americans, according to the Depression and Bipolar Support Alliance. More than 14 million Americans suffer from MDD annually. Substance abuse treatment centers can help individuals who are addicted to drugs as a result of depression.